Uric acid, hyperuricemia and vascular diseases

Frontiers in Bioscience

Volumn 17, Issue 2, 2012, Pages 656-669

  Jin, Ming ^a,b   Yang, Fan ^b   Yang, Irene ^b   Yin, Ying ^b   Luo, Jin Jun ^b,c   Wang, Hong ^b   Yang, Xiao Feng ^b  

^a Laboratory Medicine   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University School of Medicine   (United States)

Author keywords

Cardiovascular disease; Hyperuricemia; Inflammasome; Review; Uric acid

Indexed keywords

EID: 84860346199     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3950     Document Type: Article

References (121)

1. Wallace, K. L., A. A. Riedel, N. Joseph-Ridge and R. Wortmann: Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol, 31, 1582-7 (2004) (Pubitemid 39006641)
2. Becker, M. and B. J. Roessler: Hyperuricemia and gout. The Metabolic and Molecular Bases of Inherited Disease 7th ed. C. B. Scriver, AL, Sly, WS and Valle, D, Ed., McGraw-Hill, 1655-1677 (1995)
3. Abbott, R. D., F. N. Brand, W. B. Kannel and W. P. Castelli: Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol, 41, 237-42 (1988) (Pubitemid 18069583)
4. Krishnan, E., K. Svendsen, J. D. Neaton, G. Grandits and L. H. Kuller: Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med, 168, 1104-10 (2008) (Pubitemid 351749228)
5. Krishnan, E., J. F. Baker, D. E. Furst and H. R. Schumacher: Gout and the risk of acute myocardial infarction. Arthritis Rheum, 54, 2688-96 (2006) (Pubitemid 44208638)
6. Cannon, P. J., W. B. Stason, F. E. Demartini, S. C. Sommers and J. H. Laragh: Hyperuricemia in primary and renal hypertension. N Engl J Med, 275, 457-64 (1966)
7. Ford, E. S., C. Li, S. Cook and H. K. Choi: Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation, 115, 2526-32 (2007) (Pubitemid 46763226)
8. Tuttle, K. R., R. A. Short and R. J. Johnson: Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol, 87, 1411-4 (2001) (Pubitemid 32523032)
9. Lehto, S., L. Niskanen, T. Ronnemaa and M. Laakso: Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke, 29, 635-9 (1998) (Pubitemid 28145791)
10. Schretlen, D. J., A. B. Inscore, T. D. Vannorsdall, M. Kraut, G. D. Pearlson, B. Gordon and H. A. Jinnah: Serum uric acid and brain ischemia in normal elderly adults. Neurology, 69, 1418-23 (2007) (Pubitemid 47511463)
11. Roberts, J. M., L. M. Bodnar, K. Y. Lain, C. A. Hubel, N. Markovic, R. B. Ness and R. W. Powers: Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension, 46, 1263-9 (2005) (Pubitemid 43189721)
12. Siu, Y. P., K. T. Leung, M. K. Tong and T. H. Kwan: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis, 47, 51-9 (2006) (Pubitemid 41828266)
13. Niskanen, L. K., D. E. Laaksonen, K. Nyyssonen, G. Alfthan, H. M. Lakka, T. A. Lakka and J. T. Salonen: Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med, 164, 1546-51 (2004) (Pubitemid 38970476)
14. Culleton, B. F., M. G. Larson, W. B. Kannel and D. Levy: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med, 131, 7-13 (1999) (Pubitemid 29310011)
15. Wen, C. P., T. Y. David Cheng, H. T. Chan, M. K. Tsai, W. S. Chung, S. P. Tsai, M. L. Wahlqvist, Y. C. Yang, S. B. Wu, P. H. Chiang and S. F. Wen: Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. Am J Kidney Dis, 56, 273-88 (2010)
16. Popa-Nita, O. and P. H. Naccache: Crystal-induced neutrophil activation. Immunol Cell Biol, 88, 32-40 (2010)
17. Martin, W. J. and J. L. Harper: Innate inflammation and resolution in acute gout. Immunol Cell Biol, 88, 15-9 (2010)
18. Liu-Bryan, R.: Intracellular innate immunity in gouty arthritis: role of NALP3 inflammasome. Immunol Cell Biol, 88, 20-3 (2010)
19. Wu, X. W., D. M. Muzny, C. C. Lee and C. T. Caskey: Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol, 34, 78-84 (1992)
20. Wu, X., M. Wakamiya, S. Vaishnav, R. Geske, C. Montgomery, Jr., P. Jones, A. Bradley and C. T. Caskey: Hyperuricemia and urate nephropathy in urate oxidasedeficient mice. Proc Natl Acad Sci U S A, 91, 742-6 (1994) (Pubitemid 24041478)
21. Ames, B. N., R. Cathcart, E. Schwiers and P. Hochstein: Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A, 78, 6858-62 (1981) (Pubitemid 12216861)
22. Watanabe, S., D. H. Kang, L. Feng, T. Nakagawa, J. Kanellis, H. Lan, M. Mazzali and R. J. Johnson: Uric acid, hominoid evolution, and the pathogenesis of saltsensitivity. Hypertension, 40, 355-60 (2002) (Pubitemid 35006723)
23. Christen, P., W. C. Peacock, A. E. Christen and W. E. Wacker: Urate oxidase in primate phylogenesis. Eur J Biochem, 12, 3-5 (1970)
24. Wacker, W. E.: Man: sapient but gouty. N Engl J Med, 283, 151-2 (1970)
25. Tomita, M., S. Mizuno, H. Yamanaka, Y. Hosoda, K. Sakuma, Y. Matuoka, M. Odaka, M. Yamaguchi, H. Yosida, H. Morisawa and T. Murayama: Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol, 10, 403-9 (2000)
26. Chamorro, A., V. Obach, A. Cervera, M. Revilla, R. Deulofeu and J. H. Aponte: Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke, 33, 1048-52 (2002) (Pubitemid 34293590)
27. Barker, D. J., C. Osmond, J. Golding, D. Kuh and M. E. Wadsworth: Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. Bmj, 298, 564-7 (1989) (Pubitemid 19072097)
28. Jones, D. P., H. Mahmoud and R. W. Chesney: Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol, 9, 206-12 (1995)
29. Emmerson, B. T.: Effect of oral fructose on urate production. Ann Rheum Dis, 33, 276-80 (1974)
30. Kim, S. Y., J. P. Guevara, K. M. Kim, H. K. Choi, D. F. Heitjan and D. A. Albert: Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis care and research, 62, 170-80 (2010)
31. Wheeler, J. G., K. D. Juzwishin, G. Eiriksdottir, V. Gudnason and J. Danesh: Serum uric acid and coronary heart disease in 9, 458 incident cases and 155, 084 controls: prospective study and meta-analysis. PLoS Med, 2, e76 (2005)
32. Heinig, M. and R. J. Johnson: Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleveland Clinic journal of medicine, 73, 1059-64 (2006) (Pubitemid 44883981)
33. Cigolini, M., G. Targher, M. Tonoli, F. Manara, M. Muggeo and G. De Sandre: Hyperuricaemia: relationships to body fat distribution and other components of the insulin resistance syndrome in 38-year-old healthy men and women. Int J Obes Relat Metab Disord, 19, 92-6 (1995)
34. Chu, N. F., D. J. Wang, S. H. Liou and S. M. Shieh: Relationship between hyperuricemia and other cardiovascular disease risk factors among adult males in Taiwan. Eur J Epidemiol, 16, 13-7 (2000)
35. Yeh, C. J., W. H. Pan, Y. S. Jong, Y. Y. Kuo and C. H. Lo: Incidence and predictors of isolated systolic hypertension and isolated diastolic hypertension in Taiwan. J Formos Med Assoc, 100, 668-75 (2001)
36. Leite, M. L.: Uric acid and fibrinogen: agemodulated relationships with blood pressure components. J Hum Hypertens (advanced online publication September 23), 1-8 (2010)
37. Brand, F. N., D. L. McGee, W. B. Kannel, J. Stokes, 3rd and W. P. Castelli: Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol, 121, 11-8 (1985) (Pubitemid 15150683)
38. Kosugi, T., T. Nakagawa, D. Kamath and R. J. Johnson: Uric acid and hypertension: an age-related relationship? J Hum Hypertens, 23, 75-6 (2009)
39. Lu, Z., B. Dong, H. Wu, T. Chen, Y. Zhang, J. Wu and H. Xiao: Serum uric acid level in primary hypertension among Chinese nonagenarians/centenarians. J Hum Hypertens, 23, 113-21 (2009)
40. Forman, J. P., H. Choi and G. C. Curhan: Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol, 18, 287-92 (2007) (Pubitemid 46053441)
41. Blacher, J. and M. Safar: Specific aspects of high blood pressure in the elderly. J Renin Angiotensin Aldosterone Syst, 3 Suppl 1, S10-5 (2002)
42. Nakagawa, T., H. Hu, S. Zharikov, K. R. Tuttle, R. A. Short, O. Glushakova, X. Ouyang, D. I. Feig, E. R. Block, J. Herrera-Acosta, J. M. Patel and R. J. Johnson: A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol, 290, F625-31 (2006) (Pubitemid 43724964)
43. Feig, D. I., T. Nakagawa, S. A. Karumanchi, W. J. Oliver, D. H. Kang, J. Finch and R. J. Johnson: Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int, 66, 281-7 (2004) (Pubitemid 38870104)
44. Brenner, B. M., D. L. Garcia and S. Anderson: Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens, 1, 335-47 (1988)
45. Keller, G., G. Zimmer, G. Mall, E. Ritz and K. Amann: Nephron number in patients with primary hypertension. N Engl J Med, 348, 101-8 (2003) (Pubitemid 36056716)
46. Lee, J. E., Y. G. Kim, Y. H. Choi, W. Huh, D. J. Kim and H. Y. Oh: Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension, 47, 962-7 (2006) (Pubitemid 44297569)
47. Iseki, K., Y. Ikemiya, T. Inoue, C. Iseki, K. Kinjo and S. Takishita: Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis, 44, 642-50 (2004) (Pubitemid 39237608)
48. Iseki, K., S. Oshiro, M. Tozawa, C. Iseki, Y. Ikemiya and S. Takishita: Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res, 24, 691-7 (2001) (Pubitemid 33133783)
49. Bellomo, G., S. Venanzi, C. Verdura, P. Saronio, A. Esposito and M. Timio: Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis, 56, 264-72 (2010)
50. Eckel, R. H., S. M. Grundy and P. Z. Zimmet: The metabolic syndrome. Lancet, 365, 1415-28 (2005) (Pubitemid 40523737)
51. Ford, E. S., W. H. Giles and A. H. Mokdad: Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care, 27, 2444-9 (2004) (Pubitemid 39281399)
52. Malik, S., N. D. Wong, S. S. Franklin, T. V. Kamath, G. J. L'Italien, J. R. Pio and G. R. Williams: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation, 110, 1245-50 (2004) (Pubitemid 39202340)
53. Yoo, T. W., K. C. Sung, H. S. Shin, B. J. Kim, B. S. Kim, J. H. Kang, M. H. Lee, J. R. Park, H. Kim, E. J. Rhee, W. Y. Lee, S. W. Kim, S. H. Ryu and D. G. Keum: Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J, 69, 928-33 (2005) (Pubitemid 41124260)
54. Choi, H. K. and E. S. Ford: Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med, 120, 442-7 (2007) (Pubitemid 46656248)
55. Onat, A., H. Uyarel, G. Hergenc, A. Karabulut, S. Albayrak, I. Sari, M. Yazici and I. Keles: Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens, 19, 1055-62 (2006) (Pubitemid 44485960)
56. Hall, A. P., P. E. Barry, T. R. Dawber and P. M. McNamara: Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med, 42, 27-37 (1967)
57. Freedman, D. S., D. F. Williamson, E. W. Gunter and T. Byers: Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol, 141, 637-44 (1995)
58. Havel, P. J.: Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev, 63, 133-57 (2005)
59. Johnson, R. J., M. S. Segal, Y. Sautin, T. Nakagawa, D. I. Feig, D. H. Kang, M. S. Gersch, S. Benner and L. G. Sanchez-Lozada: Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr, 86, 899-906 (2007) (Pubitemid 47538288)
60. Choi, J. W., E. S. Ford, X. Gao and H. K. Choi: Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum, 59, 109-16 (2008) (Pubitemid 351171885)
61. Gao, X., L. Qi, N. Qiao, H. K. Choi, G. Curhan, K. L. Tucker and A. Ascherio: Intake of added sugar and sugar-sweetened drink and serum uric acid concentration in US men and women. Hypertension, 50, 306-12 (2007) (Pubitemid 47205778)
62. Ludwig, D. S., K. E. Peterson and S. L. Gortmaker: Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis. Lancet, 357, 505-8 (2001) (Pubitemid 32173586)
63. Schulze, M. B., J. E. Manson, D. S. Ludwig, G. A. Colditz, M. J. Stampfer, W. C. Willett and F. B. Hu: Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA, 292, 927-34 (2004) (Pubitemid 39097202)
64. Segal, M. S., E. Gollub and R. J. Johnson: Is the fructose index more relevant with regards to cardiovascular disease than the glycemic index? Eur J Nutr, 46, 406-17 (2007) (Pubitemid 350284554)
65. Brown, C. M., A. G. Dulloo, G. Yepuri and J. P. Montani: Fructose ingestion acutely elevates blood pressure in healthy young humans. Am J Physiol Regul Integr Comp Physiol, 294, R730-7 (2008) (Pubitemid 351346948)
66. Mazzali, M., J. Hughes, Y. G. Kim, J. A. Jefferson, D. H. Kang, K. L. Gordon, H. Y. Lan, S. Kivlighn and R. J. Johnson: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension, 38, 1101-6 (2001) (Pubitemid 34252813)
67. Khosla, U. M., S. Zharikov, J. L. Finch, T. Nakagawa, C. Roncal, W. Mu, K. Krotova, E. R. Block, S. Prabhakar and R. J. Johnson: Hyperuricemia induces endothelial dysfunction. Kidney Int, 67, 1739-42 (2005) (Pubitemid 40577708)
68. Cook, S., O. Hugli, M. Egli, P. Vollenweider, R. Burcelin, P. Nicod, B. Thorens and U. Scherrer: Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med Wkly, 133, 360-3 (2003) (Pubitemid 37064561)
69. Lloyd-Jones, D., R. J. Adams, T. M. Brown, M. Carnethon, S. Dai, G. De Simone, T. B. Ferguson, E. Ford, K. Furie, C. Gillespie, A. Go, K. Greenlund, N. Haase, S. Hailpern, P. M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, L. Lisabeth, A. Marelli, M. M. McDermott, J. Meigs, D. Mozaffarian, M. Mussolino, G. Nichol, V. L. Roger, W. Rosamond, R. Sacco, P. Sorlie, V. L. Roger, T. Thom, S. Wasserthiel-Smoller, N. D. Wong and J. Wylie-Rosett: Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation, e46-e215 (2010)
70. Kim, S. Y., J. P. Guevara, K. M. Kim, H. K. Choi, D. F. Heitjan and D. A. Albert: Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis and rheumatism, 61, 885-92 (2009)
71. Holme, I., A. H. Aastveit, N. Hammar, I. Jungner and G. Walldius: Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417, 734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS) J Intern Med, 558-70 (2009)
72. Feig, D. I., D. H. Kang and R. J. Johnson: Uric acid and cardiovascular risk. N Engl J Med, 359, 1811-21 (2008)
73. Andreadou, E., C. Nikolaou, F. Gournaras, M. Rentzos, F. Boufidou, A. Tsoutsou, C. Zournas, V. Zissimopoulos and D. Vassilopoulos: Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg, 724-8 (2009)
74. Annanmaki, T., A. Muuronen and K. Murros: Low plasma uric acid level in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 22, 1133-7 (2007) (Pubitemid 47067223)
75. Auinger, P., K. Kieburtz and M. P. McDermott: The relationship between uric acid levels and Huntington's disease progression. Movement disorders: official journal of the Movement Disorder Society, 25, 224-8 (2010)
76. De Vera, M., M. M. Rahman, J. Rankin, J. Kopec, X. Gao and H. Choi: Gout and the risk of Parkinson's disease: a cohort study. Arthritis and rheumatism, 59, 1549-54 (2008)
77. Schlesinger, I. and N. Schlesinger: Uric acid in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 23, 1653-7 (2008)
78. Alonso, A., L. A. Rodriguez, G. Logroscino and M. A. Hernan: Gout and risk of Parkinson disease: a prospective study. Neurology, 1696-700 (2007) (Pubitemid 350287126)
79. Andreadou, E., C. Nikolaou, F. Gournaras, M. Rentzos, F. Boufidou, A. Tsoutsou, C. Zournas, V. Zissimopoulos and D. Vassilopoulos: Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg, 111, 724-8 (2009)
80. Hink, H. U. and T. Fukai: Extracellular superoxide dismutase, uric acid, and atherosclerosis. Cold Spring Harb Symp Quant Biol, 67, 483-90 (2002) (Pubitemid 36775544)
81. Jenner, P.: Oxidative stress in Parkinson's disease. Annals of neurology, 53 Suppl 3, S26-36; discussion S36-8 (2003)
82. Hicks, M., L. S. Wong and R. O. Day: Identification of products from oxidation of uric acid induced by hydroxyl radicals. Free Radic Res Commun, 18, 337-51 (1993)
83. Squadrito, G. L., R. Cueto, A. E. Splenser, A. Valavanidis, H. Zhang, R. M. Uppu and W. A. Pryor: Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys, 376, 333-7 (2000) (Pubitemid 30210881)
84. Abuja, P. M.: Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett, 446, 305-8 (1999) (Pubitemid 29132748)
85. Bagnati, M., C. Perugini, C. Cau, R. Bordone, E. Albano and G. Bellomo: When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J, 340 ( Pt 1), 143-52 (1999) (Pubitemid 29251101)
86. Patterson, R. A., E. T. Horsley and D. S. Leake: Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. J Lipid Res, 44, 512-21 (2003) (Pubitemid 37279698)
87. Krishnan, E.: Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford), 49, 1229-38 (2010)
88. Suzuki, T.: Nitrosation of uric acid induced by nitric oxide under aerobic conditions. Nitric Oxide, 16, 266-73 (2007) (Pubitemid 46149396)
89. Zharikov, S., K. Krotova, H. Hu, C. Baylis, R. J. Johnson, E. R. Block and J. Patel: Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol, 295, C1183-90 (2008) (Pubitemid 352790338)
90. Rao, G. N., M. A. Corson and B. C. Berk: Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem, 266, 8604-8 (1991) (Pubitemid 21906552)
91. Kanellis, J., S. Watanabe, J. H. Li, D. H. Kang, P. Li, T. Nakagawa, A. Wamsley, D. Sheikh-Hamad, H. Y. Lan, L. Feng and R. J. Johnson: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension, 41, 1287-93 (2003) (Pubitemid 36706079)
92. Kang, D. H., S. K. Park, I. K. Lee and R. J. Johnson: Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol, 16, 3553-62 (2005) (Pubitemid 46211276)
93. Kato, M., I. Hisatome, Y. Tomikura, K. Kotani, T. Kinugawa, K. Ogino, K. Ishida, O. Igawa, C. Shigemasa and V. K. Somers: Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol, 96, 1576-8 (2005) (Pubitemid 41690182)
94. Long, C. L., X. C. Qin, Z. Y. Pan, K. Chen, Y. F. Zhang, W. Y. Cui, G. S. Liu and H. Wang: Activation of ATPsensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia. J Hypertens, 26, 2326-38 (2008)
95. Farquharson, C. A., R. Butler, A. Hill, J. J. Belch and A. D. Struthers: Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation, 106, 221-6 (2002) (Pubitemid 34761303)
96. Doehner, W., N. Schoene, M. Rauchhaus, F. Leyva-Leon, D. V. Pavitt, D. A. Reaveley, G. Schuler, A. J. Coats, S. D. Anker and R. Hambrecht: Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation, 105, 2619-24 (2002) (Pubitemid 34596038)
97. Kippen, I., J. R. Klinenberg, A. Weinberger and W. R. Wilcox: Factors affecting urate solubility in vitro. Ann Rheum Dis, 33, 313-7 (1974)
98. Busso, N. and A. So: Mechanisms of inflammation in gout. Arthritis Res Ther, 12, 206 (2010)
99. Shi, Y., J. E. Evans and K. L. Rock: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature, 425, 516-21 (2003) (Pubitemid 37237047)
100. Matzinger, P.: Tolerance, danger, and the extended family. Annu Rev Immunol, 12, 991-1045 (1994) (Pubitemid 24140436)
101. Barabe, F., C. Gilbert, N. Liao, S. G. Bourgoin and P. H. Naccache: Crystal-induced neutrophil activation VI. Involvment of FcgammaRIIIB (CD16) and CD11b in response to inflammatory microcrystals. Faseb J, 12, 209-20 (1998) (Pubitemid 28080191)
102. Liu-Bryan, R., P. Scott, A. Sydlaske, D. M. Rose and R. Terkeltaub: Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum, 52, 2936-46 (2005) (Pubitemid 41372129)
103. Martinon, F., V. Petrilli, A. Mayor, A. Tardivel and J. Tschopp: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 440, 237-41 (2006) (Pubitemid 43372104)
104. So, A., T. De Smedt, S. Revaz and J. Tschopp: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther, 9, R28 (2007)
105. Dinarello, C. A.: Blocking interleukin-1beta in acute and chronic autoinflammatory diseases. J Intern Med, 269, 16-28 (2011)
106. Kroemer, G., L. Galluzzi, P. Vandenabeele, J. Abrams, E. S. Alnemri, E. H. Baehrecke, M. V. Blagosklonny, W. S. El-Deiry, P. Golstein, D. R. Green, M. Hengartner, R. A. Knight, S. Kumar, S. A. Lipton, W. Malorni, G. Nunez, M. E. Peter, J. Tschopp, J. Yuan, M. Piacentini, B. Zhivotovsky and G. Melino: Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ, 16, 3-11 (2009)
107. Bergsbaken, T., S. L. Fink and B. T. Cookson: Pyroptosis: host cell death and inflammation. Nat Rev Microbiol, 7, 99-109 (2009)
108. Franchi, L., T. Eigenbrod, R. Munoz-Planillo and G. Nunez: The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol, 10, 241-7 (2009)
109. Yang, F. and X. F. Yang: New concepts in tumor antigens: their significance in future immunotherapies for tumors. Cell Mol Immunol, 2, 331-41 (2005)
110. Streilein, J. W.: Unraveling immune privilege. Science, 270, 1158-9. (1995)
111. Yin, Y., Y. Yan, X. Jiang, J. Mai, N. C. Chen, H. Wang and X. F. Yang: Inflammasomes are differentially expressed in cardiovascular and other tissues. Int J Immunopathol Pharmacol, 22, 311-322 (2009)
112. Martinon, F., A. Mayor and J. Tschopp: The inflammasomes: guardians of the body. Annu Rev Immunol, 27, 229-65 (2009)
113. Petrilli, V., S. Papin, C. Dostert, A. Mayor, F. Martinon and J. Tschopp: Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ, 14, 1583-9 (2007) (Pubitemid 47278844)
114. Eisenbarth, S. C., O. R. Colegio, W. O'Connor, F. S. Sutterwala and R. A. Flavell: Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature, 453, 1122-26 (2008) (Pubitemid 351871731)
115. Dostert, C., V. Petrilli, R. Van Bruggen, C. Steele, B. T. Mossman and J. Tschopp: Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science, 320, 674-7 (2008) (Pubitemid 351928351)
116. Dostert, C., G. Guarda, J. F. Romero, P. Menu, O. Gross, A. Tardivel, M. L. Suva, J. C. Stehle, M. Kopf, I. Stamenkovic, G. Corradin and J. Tschopp: Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS One, 4, e6510 (2009)
117. Hornung, V., F. Bauernfeind, A. Halle, E. O. Samstad, H. Kono, K. L. Rock, K. A. Fitzgerald and E. Latz: Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol, 9, 847-56 (2008)
118. Yajima, N., M. Takahashi, H. Morimoto, Y. Shiba, Y. Takahashi, J. Masumoto, H. Ise, J. Sagara, J. Nakayama, S. Taniguchi and U. Ikeda: Critical role of bone marrow apoptosis-associated speck-like protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice. Circulation, 117, 3079-87 (2008)
119. Duewell, P., H. Kono, K. J. Rayner, C. M. Sirois, G. Vladimer, F. G. Bauernfeind, G. S. Abela, L. Franchi, G. Nunez, M. Schnurr, T. Espevik, E. Lien, K. A. Fitzgerald, K. L. Rock, K. J. Moore, S. D. Wright, V. Hornung and E. Latz: NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature, 464, 1357-61 (2010)
120. Rajamaki, K., J. Lappalainen, K. Oorni, E. Valimaki, S. Matikainen, P. T. Kovanen and K. K. Eklund: Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One, 5, e11765 (2010)
121. Ginsberg, M. H., F. Kozin, M. O'Malley and D. J. McCarty: Release of platelet constituents by monosodium urate crystals. J Clin Invest, 60, 999-1007 (1977) (Pubitemid 8223125)